For researchers choosing between the two most potent compounds in this class, retatrutide currently shows a 1.52 percentage-point weight-loss advantage over tirzepatide at comparable durations, but tirzepatide carries substantially more Phase 3 evidence and a confirmed MHRA authorisation [1][2]
In summary, while GLP-1s like semaglutide and tirzepatide are clinically effective and increasingly in demand, access remains limited due to regulatory, financial, and practical barriers
Surgical treatment options Surgical options may be necessary if youve had recurrent diverticulitis or experience complications
The FDA indicated it would delay enforcement action until the District Court issued a decision on the preliminary injunction motion or until the stated deadlines, whichever came later
Retatrutide Peptide for Advanced Weight Loss and Metabolic Optimization Retatrutide is a next-generation triple agonist peptide that targets the GLP-1, GIP, and glucagon receptors